Delivra Has Untapped Potential in Cannabis-Based Therapeutics: Ubika Research

Published:

Delivra Corp.’s (TSXV:DVA) robust product portfolio targets the fast-growing transdermal delivery market

[ihc-hide-content ihc_mb_type=”show” ihc_mb_who=”reg” ihc_mb_template=”7″ ]

[/ihc-hide-content]

Ubika Research has released an analyst note on Delivra Corp. (TSXV:DVA), a specialty biotechnology company that utilizes a proprietary transdermal delivery system platform to shuttle pharmaceutical and natural molecules, through the skin, in a targeted-specific manner. Delivra’s robust product portfolio targets the fast-growing transdermal delivery market, and the Company has untapped market potential in cannabis-based therapeutics.

Ubika Research/SmallCapPower has received compensation from Delivra to provide analyst research coverage. For full disclosure please visit here >>

To read our full disclosure, please click on the button below:

Related articles

Recent articles